Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients

The absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count (AMC) and neutrophil to lymphocyte ratio (NLR) are known markers of inflammation. We evaluated whether ANC, ALC, AMC and NLR, both before and after treatment with nivolumab, are indicative markers of overal...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2018-10, Vol.13 (10), p.e0197743-e0197743
Main Authors: Khunger, Monica, Patil, Pradnya Dinkar, Khunger, Arjun, Li, Manshi, Hu, Bo, Rakshit, Sagar, Basu, Arnab, Pennell, Nathan, Stevenson, James P, Elson, Paul, Panchabhai, Tanmay S, Velcheti, Vamsidhar
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological - therapeutic use
Biological markers
Biology and Life Sciences
Biomarkers
Cancer
Carcinoma, Non-Small-Cell Lung - blood
Carcinoma, Non-Small-Cell Lung - diagnosis
Carcinoma, Non-Small-Cell Lung - drug therapy
Cell number
Chemotherapy
Dosage and administration
Drug therapy
Female
Health sciences
Hematology
Humans
Immunotherapy
Inflammation
Internal medicine
Kaplan-Meier Estimate
Leukocyte Count
Lung cancer
Lung diseases
Lung Neoplasms - blood
Lung Neoplasms - diagnosis
Lung Neoplasms - drug therapy
Lymphocytes
Lymphocytes - cytology
Lymphocytes - drug effects
Male
Medical research
Medicine and Health Sciences
Metastasis
Middle Aged
Monoclonal antibodies
Monocytes
Monocytes - cytology
Monocytes - drug effects
Neutrophils
Neutrophils - cytology
Neutrophils - drug effects
Nivolumab
Nivolumab - therapeutic use
Non-small cell lung cancer
Non-small cell lung carcinoma
Oncology
Patients
Prognosis
Statistical models
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count (AMC) and neutrophil to lymphocyte ratio (NLR) are known markers of inflammation. We evaluated whether ANC, ALC, AMC and NLR, both before and after treatment with nivolumab, are indicative markers of overall survival (OS) and evaluated change in NLR as a predictive marker of response in non -small cell lung cancer (NSCLC) patients treated with nivolumab. A total of 109 patients with advanced NSCLC treated with nivolumab were included. ANC, ALC, AMC and NLR were examined at initiation of nivolumab therapy and after two cycles. The prognostic role of ANC, ALC, AMC and NLR with OS and changes in NLR ratio were examined with Kaplan-Meier curves and proportional hazard model. Post-treatment NLR ≥5 after two cycles of nivolumab was associated with poor OS (median OS in NLR =
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0197743